Thioaptamer Diagnostic System

Award Information
Agency:
National Aeronautics and Space Administration
Branch
n/a
Amount:
$100,000.00
Award Year:
2009
Program:
SBIR
Phase:
Phase I
Contract:
NNX09CE33P
Agency Tracking Number:
084457
Solicitation Year:
2008
Solicitation Topic Code:
X10.01
Solicitation Number:
n/a
Small Business Information
AM Biotechnologies, LLC
6023 Avenue S, #228, Galveston, TX, 77551-5419
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
788679244
Principal Investigator:
Xianbin Yang
Principal Investigator
(832) 858-8779
xianbin.yang@thioaptamer.com
Business Contact:
Mark Shumbera
Business Official
(409) 771-1981
mark.shumbera@thioaptamer.com
Research Institution:
n/a
Abstract
AM Biotechnologies (AM) will develop a diagnostic system in response to SBIR Topic X10.01 Reusable Diagnostic Lab Technology that will simultaneously detect and quantify numerous protein biomarkers with excellent sensitivity. AM will enhance the current clinical gold standard immunoassay methodology by using its proprietary bead-based aptamer selection process to select dithiophosphate backbone-modified (PS2) "thio" aptamers (PS2-thioaptamers) as replacements for antibodies in immunoassays. The PS2-thioaptamers are binding agents with functionality comparable to antibodies but with very long shelf-life under ambient environment storage. The PS2-thioaptamers bind much more tightly to their targets than regular aptamers without sacrificing specificity, and are much more nuclease resistant. AM's bead-based process allows fast selection and identification of PS2-thioaptamers, which cannot be directly selected using older aptamer technologies such as Systematic Evolution of Ligands by Exponential Enrichment (SELEX). AM will demonstrate PS2-thioaptamer integration into a state-of-the-art microfluidics instrument from Sandia National Laboratory that meets NASA's form factor needs for space flight. The Phase I Project will demonstrate detection and quantification of osteocalcin (OC) using a PS2-thioaptamer in a prototype microfluidics device (TRL-4). Phase II will entail completing the panel of biomarkers for bone demineralization and delivering a prototype of the system to NASA. In Phase III, AM and Sandia will deliver a flight test system to NASA and begin FDA validation of the system for potential use in clinical diagnostics of osteoporosis as well as other conditions.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government